CLDN11

Across TCGA pan-cancer cohorts, CLDN11 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CLDN11 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CLDN11 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CLDN11 expression acts as an unfavorable survival marker.

HNSC, CESC, and OV are the cancer types where CLDN11 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	III,IV	0.169	0.726	.003	30	view →
CESC	DFS	Median	III,IV	0.215	0.738	.001	24	view →
OV	DFS	Median	All	0.165	0.541	.004	18	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CLDN11–HNSC (OS)

Open the HNSC breakdown →